Narrative review of psychedelics, psychosis risk and schizophrenia spectrum disorders

The question

How are psychedelic drugs related to psychosis and schizophrenia spectrum disorders, and could they ever have a carefully limited therapeutic role for people with those conditions?

What they did

The authors wrote a narrative review, meaning they gathered and discussed existing published work rather than running a new study or pooling results statistically. They traced the history of the idea that psychedelics mimic psychosis (the “psychotomimetic hypothesis”), compared the subjective experiences reported after psychedelics with the experiences typical of schizophrenia spectrum disorders, and reviewed proposed brain mechanisms involving serotonin, dopamine and glutamate. They then summarized clinical evidence on risk and offered recommendations.

What they found

The authors report that psychedelic experiences and schizophrenia spectrum experiences overlap in some ways but differ in important qualitative ways, which they say challenges the idea that psychedelics simply reproduce psychosis. They note that clinical evidence shows psychedelics can worsen existing psychotic illness and may trigger psychosis in vulnerable people, but that the size of these risks has not been adequately measured. They suggest that a narrow therapeutic role might exist for specific symptoms, such as negative symptoms and depression, in stable patients using low-dose, controlled approaches. The abstract reports no numerical results.

The fine print

This is a narrative review, so the studies included were chosen by the authors rather than through a systematic search, and no data were pooled or statistically combined. The abstract gives no numbers on risk, sample sizes or effect sizes, and the authors themselves state that the magnitude of psychosis risk is not adequately quantified. The suggestion of therapeutic potential in schizophrenia spectrum disorders is a hypothesis for future research, not a tested finding. This summary is based on the abstract only.

What it means

The review argues that the link between psychedelics and psychosis is more complicated than a simple “psychedelics mimic schizophrenia” model, while still affirming that people with or at risk of psychotic illness can be harmed. Any therapeutic use in this group remains untested and speculative.

Evidence grade: Very low. This is a narrative review that summarizes selected published work without a systematic search, pooled data or new participants.

This summary is based on the study’s published abstract.